Public Health Emergency - Leading a Nation Prepared
The Office of the Assistant Secretary for Preparedness and Response (ASPR) remains committed to ensuring our stakeholders receive timely and transparent communication regarding monoclonal antibody treatments currently authorized for emergency use in certain patients for the treatment of COVID-19.
Today (4/16/2021), the U.S. Food and Drug Administration (FDA) revoked the emergency use authorization (EUA) for bamlanivimab, when administered alone, to be used for the treatment of mild to moderate COVID-19 in adults and certain pediatric patients who are at high risk of disease progression or hospitalization.
Please see the full
REGEN-COV as well as bamlanivimab + etesevimab (administered together) continue to be available under EUA. There is no shortage of monoclonal antibody product. Sites that are administering COVID-19 monoclonal antibodies can continue to order bamlanivimab and etesevimab, etesevimab to pair with the current supply of bamlanivimab that the site has available, or REGEN-COV from the authorized distributer using the monitored
direct ordering process.
ASPR will continue to work with our Federal partners on COVID-19 monoclonal antibody therapies authorized for emergency use and will provide updates as they become available.
COVID19Therapeutics@hhs.gov with any questions.
Bamlanivimab was distributed to treatment sites from November 2020 through March 2021. The following table highlights the amount of bamlanivimab distributed to jurisdictions each cycle during that timeframe.
Bamlanivimab (through March 2, 2021)
Casirivimab/imdevimab (through February 2, 2021)
All Monoclonal Antibody Therapeutics
Home | Contact Us | Accessibility | Privacy Policies | Disclaimer | HHS Viewers & Players | HHS Plain Language
Assistant Secretary for Preparedness and Response (ASPR), 200 Independence Ave., SW, Washington, DC 20201
U.S. Department of Health and Human Services | USA.gov |
HealthCare.gov in Other Languages